Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 10.4% – Should You Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares were up 10.4% during mid-day trading on Thursday . The company traded as high as $26.09 and last traded at $26.01. Approximately 235,707 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 1,423,980 shares. The stock had previously closed at $23.56.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DYN shares. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Stock Performance

The stock’s 50-day simple moving average is $28.02 and its 200 day simple moving average is $34.54. The company has a market capitalization of $2.58 billion, a PE ratio of -7.12 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jason P. Rhodes sold 782 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock worth $1,443,246 over the last 90 days. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of the business. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics during the 3rd quarter valued at approximately $34,000. Point72 DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE lifted its holdings in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $62,000. Finally, KBC Group NV increased its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.